Filter News

Anadys Pharmaceuticals, Inc. To Present At The 24th Annual JP Morgan Healthcare Conference

Published: Jan 05, 2006

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it will present at the 24th Annual JP Morgan Healthcare Conference on Thursday, January 12, 2006 at 9:00 a.m. PST (12:00 p.m. EST) at the Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA. The presentation will be simultaneously webcast and can be accessed on the Company's website at www.anadyspharma.com.

Kleanthis G. Xanthopoulos, Ph.D., Anadys' President and Chief Executive Officer, will present an overview of Anadys and its clinical development and discovery programs, that will include:

* Completion of 501, 502 and 503 clinical studies of ANA975 in healthy volunteers * Upcoming 28-day study of ANA975 in patients with chronic hepatitis C virus (HCV) * Progress in Phase II ANA380 clinical trial in patients with hepatitis B virus (HBV) * Anadys' next clinical development program -- ANA773, a novel Toll-Like Receptor-7 (TLR-7) oral prodrug, to be investigated for the treatment of certain cancers * Non-nucleoside NS5B polymerase inhibitor program for HCV

Listeners are encouraged to visit the website approximately five minutes prior to Anadys' presentation to download or install any necessary software. A replay of the presentation will become available approximately one hour after the live webcast concludes and will be archived and available until January 26, 2006.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of hepatitis, other serious infections, and cancer. The Company has core expertise in Toll-Like Receptor-based small molecule therapeutics and structure-based drug design coupled with medicinal chemistry. Anadys' clinical development programs include ANA975 for the treatment of HCV and HBV, and ANA380 for the treatment of HBV. In addition, Anadys' therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the planned upcoming 28-day study of ANA975 in patients with chronic HCV and Anadys' plan to have its next clinical development program be focused on the investigation of ANA773, a novel TLR-7 oral prodrug, for the treatment of certain cancers. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular, the results of initial clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will have favorable results in future clinical trials or receive regulatory approval. In addition, Anadys' results may be affected by risks related to the implementation of its collaboration with Novartis, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, the level of effort that its collaborative partners devote to development and commercialization of its product candidates, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. These and other factors that may cause actual results to differ are more fully discussed in the "Risk Factors" section of Anadys' Form 10-Q for the quarter ended September 30, 2005. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Anadys Pharmaceuticals, Inc.

CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications of Anadys Pharmaceuticals, Inc., +1-858-530-3653,vreardon@anadyspharma.com

Back to news